We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02047513
Recruitment Status : Active, not recruiting
First Posted : January 28, 2014
Last Update Posted : July 21, 2022
ClinAssess GmbH
Information provided by (Responsible Party):

Brief Summary:

NEONAX is an interventional, prospective, randomized, controlled, open label, two sided survival phase II studies against a fixed survival probability, with an unconnected analysis of the results in both experimental arms.

Determining the impact of 2 cycles of Perioperative nab-paclitaxel/gemcitabine followed by surgery and 4 cycles of adjuvant nab-paclitaxel/gemcitabine or 6 cycles of adjuvant nab-paclitaxel/gemcitabine on the Disease free survival (DFS) rate at 18 months post randomization

Condition or disease Intervention/treatment Phase
Resectable Pancreatic Cancer Ductal Adenocarcinoma of the Pancreas Drug: perioperative nab-paclitaxel/gemcitabine Drug: adjuvant nab-paclitaxel/gemcitabine Phase 2

Detailed Description:

The planned trial will enable us to address the following issues:

  • Identification of patients who benefit from surgery. Tumor progress during intensified Perioperative chemotherapy is likely to indicate a particularly poor prognosis suggesting that these patients would not have benefitted from immediate surgery.
  • Assess tumor response/downsizing using nab-paclitaxel/gemcitabine also at the molecular level
  • Can we achieve a better systemic tumor control or reduce the metastatic spread using nab-paclitaxel/gemcitabine compared to adjuvant gemcitabine
  • Examining the effect of a more efficacious chemotherapy regimen (nab-paclitaxel/gemcitabine) in the adjuvant setting
  • Defining the impact of a perioperative or adjuvant chemotherapy with gemcitabine/nab-paclitaxel on DFS and 3-year Overall survival (OS)

Histopathological tumor regression will be evaluated in addition to tumor size measurement according to Response Evaluation Criteria In Solid Tumors (RECIST). We will establish a histopathological tumor regression score to evaluate the efficacy of the neoadjuvant treatment. For this score we will examine tumor core biopsies obtained prior to neoadjuvant treatment and histological tumor specimen after surgery in both arms.

To reliably determine R0 resections, the resected specimen will be prepared for pathology in a defined manner according to the procedure set out in the German S3 guidelines for pancreatic cancer.

This trial provides the unique opportunity in pancreatic cancer to obtain material prior to and after surgery for biomarker analysis and correlation with outcome. We will perform pharmacogenomic candidate gene analysis of hENT1 (human equilibrative nucleoside transporter-1), CDA (cell differentiation agent), DCK (Desoxycytidin-Kinase) and 5´nucleotidase in both arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 127 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group
Actual Study Start Date : July 2015
Actual Primary Completion Date : April 2021
Estimated Study Completion Date : October 2022

Arm Intervention/treatment
Experimental: perioperative nab-paclitaxel/gemcitabine
neoadjuvant chemotherapy (8 weeks) preceding surgery (3 weeks after completion of chemotherapy) followed by adjuvant chemotherapy (16 weeks, begin within 12 weeks after surgery)
Drug: perioperative nab-paclitaxel/gemcitabine
2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)

Experimental: adjuvant nab-paclitaxel/gemcitabine
Surgery followed by adjuvant chemotherapy (24 weeks, begin within 12 weeks after surgery), follow-up per patient: Until end of study or death
Drug: adjuvant nab-paclitaxel/gemcitabine
Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)

Primary Outcome Measures :
  1. Time to Disease free survival (DFS) [ Time Frame: 18 months after randomization ]
    To improve the DFS rate at 18 months in at least one arm to≥ 55%

Secondary Outcome Measures :
  1. Safety [ Time Frame: 57 months ]
    • Safety of nab-paclitaxel/gemcitabine in the neoadjuvant and adjuvant setting

  2. morbidity and mortality [ Time Frame: 7 years ]
    • pre- and postoperative morbidity and mortality in both studies

  3. toxicity [ Time Frame: 57 months ]
    • Dropout rate due to toxicity in the neoadjuvant study

  4. Disease progression [ Time Frame: 7 years ]
    • Disease progression during neoadjuvant therapy

  5. resection rate [ Time Frame: 53 months ]
    • R0 and R1 resection rate in both groups as assessed according to the German S3 guidelines

  6. Tumor response [ Time Frame: 57 months ]
    • Tumor response according to RECIST v1.1; histopathological regression based on a predefined pathological handling of the resected specimen in the perioperative study

  7. Correlation of tumor regression and R0 resection [ Time Frame: 57 months ]
    • Correlation of tumor regression and R0 resection rate with response according to RECIST v1.1 in the perioperative study

  8. Overall survival [ Time Frame: 7 years ]
    • Overall survival in both studies

  9. tumor recurrence [ Time Frame: 7 years ]
    • First site of tumor recurrence in both studies

  10. quality of life [ Time Frame: 57 months ]
    • Explorative analysis of health related quality of life in both studies

  11. pharmacogenomic markers, tumor-biomarkers and molecular analyses [ Time Frame: 57 months ]
    • Correlation of DFS, OS and tumor regression with pharmacogenomic markers, tumor-biomarkers and molecular analyses in both studies

  12. Safety [ Time Frame: 57 months ]
    • Assessment of safety

  13. Tumor response [ Time Frame: 66 months ]
    To assess tumor response using the imaging data (CT scans, MRI-scans) obtained during the trial

  14. Tumor recurrence [ Time Frame: 66 months ]
    To assess tumor recurrence using the imaging data (CT scans, MRI-scans) obtained during the trial

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically or cytological confirmed, clearly resectable ductal adenocarcinoma of the pancreas (PDAC) ≤ cT3 with no prior tumor specific treatment.
  • No evidence of metastases to distant organs (e.g. liver, peritoneum, lung).
  • Resectable tumor. Determination of resectability based on spiral CT scans with both oral and i.v. contrast enhancement or on MRI using a recent consensus definition (Resectability: Clear fat planes around the celiac artery, hepatic artery and superior mesenteric artery.)
  • Measurable tumor according to RECIST 1.1
  • ECOG performance status 0 or 1
  • Creatinine clearance ≥ 30 ml/min
  • Serum total bilirubin level ≤ 2.5 x ULN (not necessary for enrollment or randomization, but before start of neoadjuvant chemotherapy in arm A)
  • ALT and AST ≤ 2.5 x ULN (not necessary for enrollment or randomization, but before start of neoadjuvant chemotherapy in arm A)
  • In case of biliary obstruction, biliary decompression is required if the patient was randomized to receive neoadjuvant chemotherapy (arm A)
  • White blood cell count ≥ 3.5 x 106/ml, neutrophil granulocytes count ≥ 1,5 x 106/ml, platelet count ≥ 100 x 106/ml
  • Signed informed consent incl. participation in translational research
  • Age ≥ 18 years

Exclusion criteria:

  • Borderline resectable PDAC by radiologic criteria
  • Papillary cancer
  • Neuroendocrine Cancer
  • Tumor specific pre-treatment
  • Local recurrence
  • Peritoneal or other distant metastases
  • Radiographic evidence of severe portal hypertension/cavernous transformation
  • Infiltration of extrapancreatic organs (except duodenum)
  • Ascites
  • Gastric outlet obstruction
  • Global respiratory insufficiency requiring oxygen supplementation
  • Chronic infectious diseases, immune deficiency syndromes
  • Premalignant hematologic disorders, e.g. myelodysplastic syndrome
  • Disability to understand and sign written informed consent document
  • Past or current history of malignancies except for the indication under this study and curatively treated:

    • Basal and squamous cell carcinoma of the skin
    • In-situ carcinoma of the cervix
    • Other malignant disease without recurrence after at least 2 years of follow-up
  • Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 6 months before enrollment
  • Clinically relevant or history of interstitial lung disease, e.g. non-infectious pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan or chest x-ray.
  • History of or evidence upon physical examination of CNS disease unless adequately treated (e.g. primary brain tumor, seizure not controlled with standard medical therapy or history of stroke).
  • Pre-existing neuropathy > grade 1 (NCI CTCAE)
  • Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
  • Severe non-healing wounds, ulcers or bone fractions
  • Evidence of bleeding diathesis or coagulopathy
  • Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 28 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution)
  • Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of pancreatic cancer with curative intent and central intravenous line placement for chemotherapy administration.
  • Pregnancy or breastfeeding women.
  • Subjects with known allergies to the study drugs or to any of its excipients.
  • Current or recent (within the 28 days prior randomization) treatment with another investigational drug or participation in another investigational study.
  • Any psychological, familial, sociological or geographical condition potentially compromising compliance with the study protocol and the follow-up schedule; those conditions should be discussed with the patient prior to registration in the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02047513

Layout table for location information
University of Ulm, Dept. of Internal Medicine I
Ulm, Germany, 89081
Sponsors and Collaborators
ClinAssess GmbH
Layout table for investigator information
Principal Investigator: Thomas Seufferlein, Prof. Dr. University of Ulm, Dept. of Internal Medicine I
Additional Information:
Layout table for additonal information
Responsible Party: AIO-Studien-gGmbH
ClinicalTrials.gov Identifier: NCT02047513    
Other Study ID Numbers: AIO-PAK-0313
2013-005559-34 ( EudraCT Number )
AX_CL_PANC_AIO_003710 ( Other Grant/Funding Number: Celgene )
First Posted: January 28, 2014    Key Record Dates
Last Update Posted: July 21, 2022
Last Verified: July 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs